Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03970200 · ClinicalTrials.gov registry record · Phase 2
Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03970200: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT03970200 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03970200, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).
Interventions
- DRUG Antibiotics
- DRUG Penn Microbiome Therapy - 001
- DRUG Penn Microbiome Therapy - 002
- DRUG Penn Microbiome Therapy - 003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2022-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03970200
The ClinicalTrials.gov registry entry for NCT03970200 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Antibiotics is the first listed.
NCT03970200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03970200 about?
NCT03970200 is a clinical study titled "Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)". This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).
What is the current status of trial NCT03970200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-01-16. Estimated completion is 2022-05-14.
What interventions are being tested in trial NCT03970200?
The interventions under investigation include: Antibiotics (DRUG), Penn Microbiome Therapy - 001 (DRUG), Penn Microbiome Therapy - 002 (DRUG), Penn Microbiome Therapy - 003 (DRUG).
Who is sponsoring clinical trial NCT03970200?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.